Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …

Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and
pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and …

Background Although segmentectomy is a widely used surgical procedure, lobectomy is the
standard procedure for resectable non-small-cell lung cancer (NSCLC). This study aimed to …

Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …

Lung cancer is the leading cause of cancer death in Canada and a significant cause of
morbidity for patients and their loved ones. There have been rapid advances in preventing …